Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,051 recruiting studies in this area right now.
By phase
- Not applicable2,997
- Phase 21,057
- Phase 1792
- Phase 1/Phase 2437
- Phase 3436
- Phase 4234
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma327
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis132
- Type 1 Diabetes130
- Atopic Dermatitis125
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia95
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Diabetes Mellitus, Type 163
- Hodgkin Lymphoma63
- Leukemia63
- Mantle Cell Lymphoma62
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic49
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California496
- Maryland200
- Alabama178
- Florida149
- Arizona147
- Massachusetts116
- New York116
- Texas112
- Illinois83
- Colorado82
Recruiting studies6,051 total
- NCT07784309Enrolling by invitationPhase 1
Cell therapy for CD7-positive blood cancer
This study tests a new cell therapy for people with certain types of blood cancer that have returned or not responded to standard treatments. The therapy uses immune cells modified to target a marker called CD7 on cancer cells. It may help reduce or eliminate the cancer.
TianjinAges 3–70 - NCT07788118RecruitingPhase 1/Phase 2
A new car-t therapy for relapsed large b-cell lymphoma
This trial tests a new type of CAR-T cell therapy that may be better at remembering and attacking lymphoma cells. It is for people with large B-cell lymphoma that has not responded to standard treatments or has come back.
Hangzhou, ZhejiangAges 18–75 - NCT07787117Recruiting
Comparing asthma treatments: switching to a combination inhaler vs adding a daily controller
This study compares two ways to treat asthma: switching from a rescue inhaler (albuterol) to a combination inhaler (albuterol plus budesonide), versus adding a daily controller medication (either a low-dose inhaled steroid or a leukotriene modifier) while continuing albuterol. It aims to see which approach works better for people with asthma who currently use only a rescue inhaler.
Wilmington, DelawareAges 18–99 - NCT07786077Recruiting
Patient preferences for ITP treatment
This study looks at what patients with ITP prefer in their treatments. It may help doctors understand which treatment options matter most to patients like you.
East Hanover, New JerseyAges 18 years+ - NCT06522555RecruitingPhase 3
Testing Pola-ZR2 vs ZR2 for older adults with lymphoma
This trial tests a new combination of drugs (Pola-ZR2) against a standard combination (ZR2) for older adults with newly diagnosed diffuse large B-cell lymphoma. It aims to see if the new mix is more effective and safe.
ShanghaiAges 70 years+ - NCT06532461Recruiting
Comparing 3 vs 7 day insulin pump wear in teens with type 1 diabetes
This study tests if wearing an insulin pump set for 7 days is as safe and effective as changing it every 3 days. It is for children and teens with type 1 diabetes who already use the Medtronic 780G system.
Herlev, CapitalAges 7–18 - NCT06541860Recruiting
Study of daratumumab and lenalidomide for resistant multiple myeloma
This trial tests a combination of two drugs, daratumumab and lenalidomide, for patients with multiple myeloma that has not responded to previous treatments. It aims to see if this regimen can help when other therapies have stopped working.
Pavia, PVAges 18 years+ - NCT06541626Recruiting
Study of CNS inflammatory demyelinating diseases
This study follows people with certain inflammatory conditions of the brain and spinal cord (like MS, NMOSD, or MOGAD) to learn more about their disease. If you join, you will help researchers understand these conditions better.
Guangzhou, GuangdongAges 18–65 - NCT06546033Recruiting
Intermittent fasting and Mediterranean diet for multiple sclerosis
This study tests whether a combination of intermittent fasting (eating only during certain hours) and a Mediterranean diet (rich in fruits, vegetables, whole grains, and healthy fats) can help improve symptoms in women with multiple sclerosis (MS). If you are a woman with MS and not in an active flare-up, this trial may offer a new way to manage your condition through diet.
Niğde, BorAges 18–65 - NCT07778459Recruiting
Liver transplant study for people with HIV
This study tests whether it's safe and effective for people with HIV to receive a liver transplant from a donor who also has HIV. It aims to expand access to transplants for people with HIV.
Baltimore, MarylandAges 18 years+ - NCT07779460Recruiting
Comparing two multiple sclerosis medicines in everyday practice
This study compares how well two medicines, Kesimpta and Ocrevus, work for people with multiple sclerosis when used in real life. It looks at patient records to see which treatment might be more effective.
East Hanover, New JerseyAges 18–100 - NCT07776743RecruitingPhase 2
Testing a new oral drug for relapsing-remitting multiple sclerosis (RRMS)
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
Beijing, Beijing MunicipalityAges 18–65 - NCT07783425RecruitingPhase 3
Treatment for moderate-to-severe eczema
This study tests a new medicine called Tilrekimig for people with moderate-to-severe eczema (also called atopic dermatitis) whose symptoms have not improved with creams or ointments. The goal is to see if this medicine helps reduce symptoms and improve skin condition.
Phoenix, ArizonaAges 12 years+ - NCT07779265Recruiting
Probiotic supplement for gut health in healthy adults
This trial tests a daily probiotic supplement's effect on digestion, immune health, and overall well-being. If you're a healthy adult, you may help discover if this product can make you feel better day-to-day.
TrierAges 18–65 - NCT07782996RecruitingPhase 3
Study of a new asthma drug for people with uncontrolled asthma
This study is testing whether an investigational drug called GSK5784283 can improve asthma control compared to a placebo. It is for people with uncontrolled asthma who are already on standard daily asthma medications.
Miami Lakes, FloridaAges 12–80 - NCT07780643RecruitingPhase 3
Asthma study for uncontrolled asthma on inhaled steroids
This study is testing an investigational medication for people with uncontrolled asthma. Participants must have moderate-to-severe asthma, be on appropriate maintenance therapy, and meet specific safety criteria.
Miami Lakes, FloridaAges 12–80 - NCT07776210RecruitingPhase 3
Eye drops for chronic dry eye after stem cell transplant
This trial tests an eye drop solution for people with chronic dry eye caused by graft-versus-host disease after a stem cell transplant. It aims to see if the drops can reduce eye discomfort and improve the eye surface.
Beverly Hills, CaliforniaAges 18 years+ - NCT06208137Recruiting
Using immune risk score to guide recovery after stem cell transplant
This study uses a special score (immune risk score) to check how well your immune system rebuilds after a half-matched stem cell transplant. The goal is to find patients who might need extra help with immune recovery.
Tianjin, Tianjin MunicipalityAges 16 years+ - NCT07780097Enrolling by invitation
Starting opioid addiction medication after a hospital stay
This study helps people who are in the hospital for opioid use disorder start a medication like methadone or buprenorphine after they leave the hospital. It aims to make starting treatment easier and improve recovery.
Cincinnati, OhioAges 18 years+ - NCT07779018RecruitingPhase 2
CAR-T cell therapy after second-line treatment for aggressive B-cell lymphoma
This trial tests a type of immunotherapy called CAR-T cell therapy, which uses your own immune cells to fight lymphoma. It is for people who have already responded well to a second round of chemotherapy and are at high risk of the cancer coming back. The goal is to see if this treatment can keep the cancer away longer.
BeijingAges 18–85 - NCT07783074Recruiting
Fatigue study using digital outcomes in multiple sclerosis and long COVID
This study is investigating fatigue using digital outcomes in people with multiple sclerosis, long COVID, and healthy volunteers. Participants must own a smartphone, be fluent in German or English, and be willing to provide informed consent. Exclusion criteria include having taken certain medications recently, being pregnant or lactating, or having additional health conditions that could affect fatigue or the autonomic nervous system.
Basel, BaselAges 18–65 - NCT07782944Recruiting
CD38 PET scan for multiple myeloma
This study uses a special PET scan that looks for a protein called CD38 on myeloma cells to see if it can better find and track multiple myeloma compared to the standard PET scan. It might help doctors plan your treatment more precisely.
Guilin, GuangxiAges 18 years+ - NCT07779772Recruiting
Diet changes for children with eosinophilic gut disorders
This trial compares different elimination diets to see which one best reduces inflammation in children with eosinophilic gastrointestinal disorders. Your child might have fewer symptoms and a better outcome if the right diet is found.
Adana, SarıcamAges 2–18 - NCT07780123Recruiting
Nature-based activities for young children in social housing areas
This study tests whether kindergartens can add more nature-based activities (like playing outdoors in green areas) for children aged 4-7. It looks at how feasible this is and what effects it might have on children's well-being.
FrederiksbergAges 4 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,051 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,083 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.